These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14999225)

  • 21. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction.
    Koornstra JJ; Jalving M; Rijcken FE; Westra J; Zwart N; Hollema H; de Vries EG; Hofstra RW; Plukker JT; de Jong S; Kleibeuker JH
    Eur J Cancer; 2005 May; 41(8):1195-202. PubMed ID: 15911244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
    Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F
    Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
    Armeanu S; Lauer UM; Smirnow I; Schenk M; Weiss TS; Gregor M; Bitzer M
    Cancer Res; 2003 May; 63(10):2369-72. PubMed ID: 12750253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Specific antitumor effect of adeno-associated virus vector carrying TRAIL gene under the control of hTERT promoter].
    Qi R; Cai Y; Li BH; Lin ZX; Gu JF
    Ai Zheng; 2008 Oct; 27(10):1026-33. PubMed ID: 18851780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter.
    He LF; Wang YG; Xiao T; Zhang KJ; Li GC; Gu JF; Chu L; Tang WH; Tan WS; Liu XY
    Cancer Lett; 2009 Dec; 286(2):196-205. PubMed ID: 19564073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S; Singh TR; Srivastava RK
    Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein.
    Wu X; He Y; Falo LD; Hui KM; Huang L
    Mol Ther; 2001 Mar; 3(3):368-74. PubMed ID: 11273779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins.
    Hu B; Zhu H; Qiu S; Su Y; Ling W; Xiao W; Qi Y
    Biochem Biophys Res Commun; 2004 Dec; 325(4):1153-62. PubMed ID: 15555548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus.
    Griffith TS; Broghammer EL
    Mol Ther; 2001 Sep; 4(3):257-66. PubMed ID: 11545617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects.
    Wenger T; Mattern J; Haas TL; Sprick MR; Walczak H; Debatin KM; Büchler MW; Herr I
    Cancer Gene Ther; 2007 Mar; 14(3):316-26. PubMed ID: 17186015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
    Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
    Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L; Fang B
    Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions.
    Begue B; Wajant H; Bambou JC; Dubuquoy L; Siegmund D; Beaulieu JF; Canioni D; Berrebi D; Brousse N; Desreumaux P; Schmitz J; Lentze MJ; Goulet O; Cerf-Bensussan N; Ruemmele FM
    Gastroenterology; 2006 Jun; 130(7):1962-74. PubMed ID: 16762619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
    Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
    Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL; Earel JK; Griffith TS
    Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
    Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
    J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.